![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Graft-versus-host disease (GVHD) is caused by a pathologic and destructive response of the organism as a result of the interaction between donor immunocompetent T lymphocytes and the recipient tisular antigens1. Graft-versus-host disease is considered a serious complication of hematopoietic stem cell transplantation. The skin, oral cavity and lungs are commonly affected organs. Among these complications bronchiolitis obliterans syndrome is a serious complication, which even can be life-threatening. Therefore, this research aims to do a clinical observation on the safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of bronchiolitis obliterans after allogeneic haematopoietic stem cell transplantation. Fifteen patients were included in this study, who received allogeneic hematopoietic stem cell transplantation. Among these patients, both of them were treated with azithromycin, montelukast, glucocorticoid and pirfenidone. Two of them did not receive second line anti-rejection treatment due to economic reasons, and three of them were treated with mesenchymal stem cells. These bronchiolitis obliterans syndrome-related symptoms such as shortness of breath, chest tightness and wheezing have improved. Two of them died due to bronchiolitis obliterans syndrome related complications such as respiratory failure. Two of them not only improve the symptoms but also increased the FEV1/FVC, who were treated with mesenchymal stem cells. The comprehensive treatment regimen containing imatinib and ruxolitinib is safe and effective and mesenchymal stem cell is a promising treatment option to improve the prognosis of post-HSCT BOS.
Disclosure statement
No potential conflict of interest was reported by the authors.
Data sharing statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Additional information
Funding
Notes on contributors
Ziye Li
Ziye Li, graduated from Hebei Medical University with a Ph.D. After graduation, he has been engaged in the diagnosis and treatment of malignant hematological diseases. The research focus is on the treatment of malignant hematological diseases with allogeneic hematopoietic stem cell transplantation.
Yongqi Wang
Yongqi Wang, from Henan Cancer Hospital, is engaged in the diagnosis and treatment of malignant hematological diseases, researching allogeneic hematopoietic stem cell transplantation in the treatment of malignant hematological diseases.
Gangping Li
Gangping Li, from Henan Cancer Hospital, is engaged in the diagnosis and treatment of malignant hematological diseases, researching allogeneic hematopoietic stem cell transplantation in the treatment of malignant hematological diseases.
Nan Ma
Nan Ma, from Henan Academy of Medical Sciences, engaged in stem cell research, researching stem cell therapy for chronic graft-versus-host disease.
Minghui Li
Minghui Li, from Henan Cancer Hospital, is engaged in the diagnosis and treatment of malignant hematological diseases, researching allogeneic hematopoietic stem cell transplantation in the treatment of malignant hematological diseases.
Fangfang Yuan
Fangfang Yuan, from Henan Cancer Hospital, is engaged in the diagnosis and treatment of malignant hematological diseases, researching allogeneic hematopoietic stem cell transplantation in the treatment of malignant hematological diseases.
Yuewen Fu
Yuewen Fu, from Henan Cancer Hospital, is engaged in the diagnosis and treatment of malignant hematological diseases, researching allogeneic hematopoietic stem cell transplantation in the treatment of malignant hematological diseases.
Li Wang
Li Wang, from Henan Academy of Medical Sciences, engaged in stem cell research, researching stem cell therapy for chronic graft-versus-host disease.